Vaxcyte, Inc.
Vaxcyte, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 6 upcoming events on record.
Cash runway is approximately 15.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 4, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| January 15, 2027 | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 | Trial Milestone | Phase 3 |
| March 15, 2027 | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination | Trial Milestone | Phase 3 |
| March 15, 2027 | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age | Trial Milestone | Phase 3 |
| December 15, 2027 | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants | Trial Milestone | Phase 2 |
| December 15, 2027 | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults | Trial Milestone | Phase 1 |
Track PCVX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open PCVX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.